Proteins and Peptides

24 Jun 2018 Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
22 Jun 2018 Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia
21 Jun 2018 Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials
19 Jun 2018 Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
19 Jun 2018 Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
19 Jun 2018 Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
19 Jun 2018 Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B
19 Jun 2018 Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress
15 Jun 2018 Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
15 Jun 2018 Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
14 Jun 2018 BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
14 Jun 2018 ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States
11 Jun 2018 FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label
11 Jun 2018 OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity
11 Jun 2018 AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
08 Jun 2018 Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
06 Jun 2018 Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome
05 Jun 2018 U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
04 Jun 2018 Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting
03 Jun 2018 Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carcinoma
01 Jun 2018 MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
31 May 2018 Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI-PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
31 May 2018 Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial
29 May 2018 Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
28 May 2018 Octapharma Share Promising Preclinical Data for SubQ-8, a Novel Subcutaneous Recombinant FVIII, at WFH 2018

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up